Login / Signup

Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Alyssa I Clay-GilmourAbdul R RishiLynn R GoldinAlexandra J Greenberg-WorisekSara J AchenbachKari G RabeMatthew John MaurerNeil E KayTait D ShanafeltTimothy G CallJ Brice WeinbergNicola J CampJames R CerhanJose LeisAaron NormanDavid L MurraySundararajan Vincent RajkumarNeil E CaporasoOla LandgrenMary L McMasterSusan L SlagerCeline M Vachon
Published in: Blood cancer journal (2019)
Chronic lymphocytic leukemia (CLL) and its precursor, monoclonal B-cell lymphocytosis (MBL), are heritable. Serumfree light-chain (sFLC) measures are a prognostic factor for CLL, but their role in susceptibility to CLL is not clear. We investigated differences between sFLC measurements in pre-treatment serum from five groups to inform the association of sFLC with familial and sporadic CLL: (1) familial CLL (n = 154), (2) sporadic CLL (n = 302), (3) familial MBL (n = 87), (4) unaffected first-degree relatives from CLL/MBL families (n = 263), and (5) reference population (n = 15,396). The percent of individuals having elevated monoclonal and polyclonal sFLCs was compared using age-stratified and age- and sex-adjusted logistic regression models. In age groups >50 years, monoclonal sFLC elevations were increased in sporadic and familial CLL cases compared to the reference population (p's < 0.05). However, there were no statistically significant differences in sFLC monoclonal or polyclonal elevations between familial and sporadic CLL cases (p's > 0.05). Unaffected relatives and MBL cases from CLL/MBL families, ages >60 years, showed elevated monoclonal sFLC, compared to the reference population (p's < 0.05). This is the first study to demonstrate monoclonal sFLC elevations in CLL cases compared to controls. Monoclonal sFLC levels may provide additional risk information in relatives of CLL probands.
Keyphrases
  • chronic lymphocytic leukemia
  • multiple myeloma
  • late onset
  • early onset
  • prognostic factors
  • healthcare
  • amyotrophic lateral sclerosis
  • mass spectrometry
  • high resolution
  • replacement therapy